Health status changes in COPD patients after real-life switch from tiotropium or salmeterol/fluticasone to indacaterol/glycopyrronium using the EQ-5D-3L instrument: results from the POWER study

S. Anees (Windsor, Canada), A. Mcivor (Hamilton, Canada), K. Chapman (Toronto, Canada), I. Mayers (Edmonton, Canada), D. Rochdi (Dorval, Canada), D. Prefontaine (Dorval, Canada), A. Kaplan (Toronto, Canada)

Source: International Congress 2018 – COPD management
Session: COPD management
Session type: Thematic Poster
Number: 4380
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Anees (Windsor, Canada), A. Mcivor (Hamilton, Canada), K. Chapman (Toronto, Canada), I. Mayers (Edmonton, Canada), D. Rochdi (Dorval, Canada), D. Prefontaine (Dorval, Canada), A. Kaplan (Toronto, Canada). Health status changes in COPD patients after real-life switch from tiotropium or salmeterol/fluticasone to indacaterol/glycopyrronium using the EQ-5D-3L instrument: results from the POWER study. 4380

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: